AzTrials
AzTrials

Diabetes Mellitus, Type 2LIBERATENCT05261906

The FreeStyle Libre Enabled Reduction of A1c Through Effective Eating and Exercise Study

A study testing LIBERATE in people with Diabetes Mellitus, Type 2, run by Western University, Canada at 1 site in Canada.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This two-year multisite, real-world, before-after prospective six-month pilot study utilizing a single-group cohort design (n=184) which will first occur in London, Ontario (n=92) through the St. Joseph's Primary Care for Diabetes Support (PCDSP) program. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diabetes Mellitus, Type 2
What is being tested?
LIBERATE
Could I receive a placebo?
No, everyone receives an active treatment
How many people
184 participants
Where
1 siteCanada
Study dates
26 Sep 2022to Oct 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • • Diagnosis of Type 2 diabetes, age >18 years old
  • Baseline HbA1c ≥ 8.0% (if no recent A1c (last 3 months) you can ask, or we will ask them to complete a new test).
  • Naïve to Flash glucose monitors BUT interested in using this technology
  • Ownership of either a smartphone (iPhone v7 (iOS of 13.2+) or Samsung Galaxy Note 8, S7 Edge, S8, S8+, S9, S10; Google Pixel, Pixel 2, Pixel 2 XL, Pixel 3, Pixel 3 XL, Pixel 4, Pixel 4 X; LG Nexus 5X (with Android OS of 8 or higher). Other smartphones may be compatible but must be confirmed. https://freestyleserver.com/Payloads/IFU/2022/q2/ART39109-002_rev-J-web.pdf
  • Have an email address
  • Access to Internet connection
  • Physician cleared to participate in exercise

Who cannot join

  • • Lack of access/knowledge of technology that would prevent virtual participation (Self-reported)
  • • Language barrier, severe mental illness, cognitive impairment or significant/unstable psychiatric disease limiting group participation
  • Pregnancy
  • Active or untreated conditions that would preclude the safe participation of exercise i.e., foot ulcer, CVD, uncontrolled HTN, retinopathy, etc.
  • Recent (<3 months) medically unstable condition i.e., recent MI, stroke, hospitalization, etc.
  • Inability to participate in the full program (e.g., upcoming surgery, relocating, etc.…)

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • St. Joseph's Family Medical and Dental Centre

    London, Ontario, N6G 1J1

Other trials in Canada

About this study

Official title: The Libre Enabled Reduction of A1c Through Effective Eating and Exercise Study: LIBERATE

This two-year multisite, real-world, before-after prospective six-month pilot study utilizing a single-group cohort design (n=184) which will first occur in London, Ontario (n=92) through the St. Joseph's Primary Care for Diabetes Support (PCDSP) program. To test fidelity, the intervention will be delivered again in Hamilton, Ontario through the Hamilton Health Sciences' Boris Clinic in Diabetes Care and Research Program (n=92).

Participants will begin by attending the first class at the PCDSP clinic to complete baseline fitness testing as well as receive/set up their wearable technology (FitBit Inspire 2™ and FreeStyle® Libre sensors). Two weeks of baseline data collection will following (glucose values and step counts). Five bi-weekly, followed by three monthly, one-hour videoconferencing group education classes via Microsoft Teams video platform will be offered. Participants will be given the choice to communicate with the LIBERATE clinical team (exercise specialist, physician, and/or registered) weekly between the group classes using their preferred method of communication i.e., email.

Classes will offer FreeStyle® Libre-assisted behavioural coaching (i.e., nutrition and exercise). FreeStyle® Libres will be used during the first three months of the program and optionally in the last three months of the intervention. The FitBit Inspire 2™ monitors will be worn for six months. Participants are provided the option to receive individualized aerobic and resistance training prescriptions. The primary outcome is change in glycated hemoglobin. A main goal of this study is to create a "toolkit" for other Canadian Diabetes Management centres (DMCs) to use in the future.

Read the detailed description

PROTOCOL TIMELINE

  1. Pre-study Eligibility Criteria Confirmation and Study Review and Scheduling of Participant

The research coordinator will phone potential participants to answer any questions about the study and confirm eligibility criteria. One the same call, the research coordinator will be setting up a phone call time (within the week) to review the LOI with the potential participant. After the phone call, the research coordinator will send the LOI for review via email. The time from this call to program start may vary between participants. This is due to the need to fill the group capacity of 6-8 participants/class before initiating a participant.

If a patient self-refers from the community, we will access OLIS for recent blood work. If an A1c has not been completed in the last 3 months, we will need to consent them over the phone using the e-consent via REDCap first and then they will be given an OHIP lab requisition to complete the test within one week. This is done so that potential participants are not having to go through the entire onboarding testing before knowing if they are eligible to participate in the study.

On the phone call (within the week of the pre-screening call), we will review the Letter of Information and Consent with the participant. We will answer any questions they may have.

  1. Time 1: ORIENTATION SESSION

The first group session will hopefully be in-person. If however we are unable to do so, we will use the WebEx platform to orient and teach participants about the technology they will be using during the study. This session will be run by a CDNE and the research coordinator.

We will review study expectations briefly at the session, answer any remaining questions about the LOI. Then, informed consent will be obtained virtually using individualized REDCap links to sign the board approved e-consent method.

Topics to be covered during this session will include; how to set-up and use the wearable fitness tracker (FitBit Inspire 2™) and FreeStyle® Libre, and their associated smartphone apps. To ensure safety to participate in exercise, the modified Physical Activity Readiness Questionnaire (PAR-Q) will also be administered by either and RN or MD at this time (Freehan et al., 2018). If they pass the PAR-Q, baseline fitness testing (see "other measures section" for description of the six-minute walk test (6MWT) and handgrip testing protocol) will also occur during this session. Participants will also complete their baseline stride length assessment, weight, and height, blood pressure and waist circumference assessments. Baseline questionnaires will be completed via online surveys.

Once consent is obtained, and medical suitability is confirmed baseline physiological data (glycated hemoglobin (HbA1c), medications, past medical history) will be extracted from the PCDSP electronic medical record (EMR) WebDR. If the patient is referred to us by a family physician we will ask them to include these details in the referral.

  1. Intervention Week 1-12 (IW2-12): Biweekly Virtual Sessions
  • Within Intervention week 1, participants will be randomly prompted to complete a 24h-hour dietary recall through the ASA-24 2018, completed 3 times within the week. All participants will complete this measurement; each participant will be assigned to a random day within the week to avoid planning healthy meals (and creating biased results).
  • Baseline Step Count and FreeStyle Libre Data Collection (2 weeks) after attending the on-boarding session

Then after the two week baseline, participants will attend biweekly virtual coaching sessions (total of six (6) classes including the on-boarding session). Please see below for an outline of the proposed content delivered during the classes (coaching program: behavioural, nutrition and exercise). Prior to each virtual group i.e. the night before, participants will be required to email: 1) wearable fitness tracker data (screen shot of their exercise/step summary), 2) resistance training log if engaging with resistance exercise as a method of glucose regulation and 3) uploaded sensor data to LibreView. This information will then be reviewed by a clinic exercise specialist/registered nurse/ physician prior to the group to determine individualized exercise progression, and suggested modifications to diet. Wearable fitness study-related data will NOT be collected via these means (email), but rather via data export from the fitbit.com desktop platform completed by the research co-ordinator. Participants will provide us an email address to use on their behalf, and we will provide a password for participants to use to log on to their smartphone app (or desktop platform, if they wish) during the course of the study. After the study, participants will be granted permission to change their password to a desired password, and study investigators will lose access to this account.

At the end of the 12 weeks, participants will be asked to go have their blood tested within (given a blood requisition for A1c testing). They will also be asked to come into the clinic to have their weight, height, and waist circumference measured. Participants will also re-complete the 6MWT and handgrip strength test. At the same time, participants will be given their final three FreeStyle Libre 2 sensors.

Within Intervention week 12, participants will be randomly prompted to complete a 24h-hour dietary recall through the ASA-24 2018, three times within the week. All participants will complete these measurements; each participant will be assigned to a random day within the week. When prompted via email, participant will be asked to complete a recall of the past day from midnight to midnight of all that they ate and drank.

  1. Intervention Week 12-24 (IW12-24): Monthly Virtual Sessions Coaching during the remaining 3 virtual group education classes (on Microsoft Teams) of the last 3 months of the intervention will be similar in design to IW2-12, but will focus on creating lasting behaviour change. Participants will be given the choice whether to wear any or all of their three (3) Libre 2 sensors and/for continue to wear the loaned FitBit Inspire 2™. Sensor usage will be tracked (i.e., Participant 3 used 2/3 sensors).
  2. Follow-up Period (Week 24) Participants will be contacted to set up an appointment to review the follow-up questionnaires in clinic with the research coordinator. The questionnaires to be completed are: the Stanford Diabetes Self-Efficacy Scale, EQ-5D-5L, and an exit survey. Participants will also return the FitBit Inspire 2™ back to the clinic. Participants will also attend their fitness testing (6MWT and handgrip strength test) at the clinics. Participants will receive a A1c requisition again to have A1c tested again within the week.

Within Intervention week 24, participants will be randomly prompted to complete a 24h-hour dietary recall through the ASA-24 2018, completed 3 times within the week. All participants will complete this measurement; each participant will be assigned to a random day within the week. When prompted via email, participant will be asked to complete a recall of the past day from midnight to midnight of all that they ate and drank.

Intervention Description:

  1. Intervention Week 2-12 (IW2-12): Biweekly Virtual Sessions

Participants will attend biweekly virtual coaching sessions (total of five (5) classes). Prior to each virtual group i.e. the night before, participants will be required to email: wearable fitness tracker information (resistance exercise log if applicable) and uploaded sensor data to LibreView. This information will be reviewed by a clinic registered nurse or physician prior to the group to determine individualized exercise progression, and suggested modifications to diet.

  1. Intervention Week 12-24 (IW12-24): Monthly Virtual Sessions

Coaching during the remaining 3 classes of the last 3 months of the intervention will be similar in design to IW2-12, but will focus on creating lasting behaviour change. Participants will be given the choice whether or not to wear any or all of their three (3) Libre sensors.

  1. Coaching Program Description

At the beginning of each class, participants will be given their new exercise AND nutrition goal or prescription. For the remainder of the 1-hour class, the focus will be to coach participants to infer and draw connections between their food/activity choices and glycemic responses. This will be done using motivational interviewing guided by Self Determination Theory and Kolb's cycle of experiential learning and Libre glycemic examples from volunteering participants. Participants will be encouraged to have their Libre results from the previous two weeks in front of them to use during these exercises. Focusing on habit formation will also be a key coaching goal.

Participants will for the most part lead the direction of the group discussion, with questions raised at the start of each session by the group facilitator(s): barriers or motivators in the last two weeks, goals achieved, etc. The clinical group facilitators coaching the group will provide suggestions or solutions to issues i.e. technology issues, how to safely exercise in a pandemic environment, how to reduce glycemic variability by choosing lower glycemic foods, etc. Didactic teaching will be kept to a minimum to optimize adult learning behaviour and theory.

  1. FreeStyle Libre Assisted Nutrition Coaching Description

Focus of the material presented during these classes will be to guide participants towards the consumption of lower carbohydrate and lower glycemic foods, while maintaining adequate nutritional needs for activity and health. General principles will be provided at the start of the program, with participants then learning, based on their FreeStyle Libre glycemic readings which foods affect their blood sugars in both positive and negative ways. The goal will be to empower participants to not only find day-to-day foods that work for their diabetes, but also to be able to critically evaluate food choices when the foods consumed either raise or lower blood sugars to undesired levels.

  1. Exercise Prescriptions

Step, aerobic and resistance training prescriptions will be updated biweekly for baseline-month 3 (within one day of group classes) and will continue on the same schedule (biweekly) after month 3 to month 6.

Participants will be encouraged to interrupt their prolonged sitting with frequently (every 20 to 45 minutes, under an hour) with 2-3 minutes light-intensity physical activity and to decrease overall daily sedentary time. To give participants daily feedback and reminders to get up and move every hour, participants are advised to achieve their hourly movement goals (defined as an hour with 250 steps or more, defined and measured by the FitBit Inspire 2™) or 2 to 3 minutes of light physical activity.

Being tested
LIBERATE
Keywords
lifestyle medicine, flash glucose monitor, exercise prescription, nutrition, biofeedback, self-monitoring, wearable activity monitor, virtual care, group education, coaching, behaviour change
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LIBERATEBehavioural

    Five bi-weekly, followed by three monthly, one-hour videoconferencing group education classes via Microsoft Teams video platform will be offered. Participants will be given the choice to communicate with the LIBERATE clinical team (exercise specialist, MD, and/or RN) weekly between the group classes using their preferred method of communication i.e., email.

    Classes will offer FreeStyle® Libre-assisted behavioural coaching (i.e., nutrition and exercise). FreeStyle® Libres will be used during the first three months of the program and optionally in the last three months of the intervention. The FitBit Inspire 2™ monitors will be worn for six months. Participants are provided the option to receive individualized aerobic and resistance training prescriptions.

Study groups in NCT05261906
Study groupRoleWhat they receive
LIBERATE InterventionExperimentalNot described
Receives: Behavioral: LIBERATE

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in HbA1c from Baseline

    HbA1c measured at baseline, 3 months, and 6 months

    Measured: 6 months

Secondary outcomes (2)
  1. Change in total daily basal insulin use from baseline

    Daily basal insulin use, measured at baseline, 3 months, and 6 months

    Measured: 6 months

  2. Change in rapid insulin use from Baseline

    Rapid insulin use, measured at baseline, 3 months, and 6 months

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Mar 2022
  2. Study start26 Sep 2022
  3. Primary completionOct 2025 (estimated)
  4. Study completionOct 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
All participants will be in the treatment group. This is a multisite intervention; the intervention will be first delivered at the Primary Care for Diabetes Support Program in London, Ontario with 92 participants. Following intervention completion in London, ON, the Boris Clinic in Diabetes Care and Research Program (DCRP) in Hamilton, ON will deliver the intervention as a fidelity check, with another 92 participants.
Masking
None (open label)
Enrolment
184 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05261906
Sponsor's protocol ID
119334
Acronym
LIBERATE
Status last verified
Jun 2025
First submitted
27 Jan 2022
Last updated
5 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing LIBERATE in people with Diabetes Mellitus, Type 2, run by Western University, Canada at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 5 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in HbA1c from Baseline (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in